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Abstract
Very solid evidence suggests that the core of full length PrPSc is a 4-rung β-solenoid, and
that individual PrPSc subunits stack to form amyloid fibers. We recently used limited proteol-
ysis to map the β-strands and connecting loops that make up the PrPSc solenoid. Using
high resolution SDS-PAGE followed by epitope analysis, and mass spectrometry, we iden-
tified positions ~116/118, 133–134, 141, 152–153, 162, 169 and 179 (murine numbering)
as Proteinase K (PK) cleavage sites in PrPSc. Such sites likely define loops and/or borders
of β-strands, helping us to predict the threading of the β-solenoid. We have now extended
this approach to recombinant PrPSc (recPrPSc). The term recPrPSc refers to bona fide
recombinant prions prepared by PMCA, exhibiting infectivity with attack rates of ~100%.
Limited proteolysis of mouse and bank vole recPrPSc species yielded N-terminally trun-
cated PK-resistant fragments similar to those seen in brain-derived PrPSc, albeit with
varying relative yields. Along with these fragments, doubly N- and C-terminally truncated
fragments, in particular ~89/97-152, were detected in some recPrPSc preparations; similar
fragments are characteristic of atypical strains of brain-derived PrPSc. Our results suggest
a shared architecture of recPrPSc and brain PrPSc prions. The observed differences, in par-
ticular the distinct yields of specific PK-resistant fragments, are likely due to differences in
threading which result in the specific biochemical characteristics of recPrPSc. Furthermore,
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Author summary
PrPSc Prions propagate by inducing the refolding of the natively folded normal cellular
prion protein (PrPC) into the prion conformation in brain and other mammalian tissues
(wild-type). Understanding the structure of PrPSc is essential to understanding how PrPSc
prions propagate. The secondary structure of PrPC is composed of four α-helical regions,
two very small β-sheets and random coil, while PrPSc is composed entirely of β-sheets and
random coil. The β-sheets of PrPSc wind four times to form a spring-like 4-rung β-sole-
noid. The rungs are connected by stretches of random coil. We have used proteinase K
(PK), to cleave these random coil connecters, allowing us to identify the location of the
more PK-resistant β-strand stretches within wild-type PrPSc. In this work, we use recom-
binant PrPSc, (in vitro generated infectious prions) to show that patterns of PK cleavage
for recombinant and wild-type PrPSc are very similar, indicating that they share a com-
mon architecture. This also means that recombinant PrPSc is a true surrogate for wild-
type PrPSc. Since recombinant PrPSc is derived from recombinant PrP, future structural
studies employing specific amino acid or stable-isotope labeled amino acid substitutions
are easily achievable. Such substitutions are essential for NMR studies.
Introduction
Prions are infectious proteins [1, 2]. They propagate by inducing the host’s isosequential nor-
mal cellular prion protein (PrPC) to adopt the infecting prion’s conformation [2]. Prions can
be transmitted from one organism to another by different means, for example by oral route [2,
3], hence their infectious nature. Prions pique an extraordinary theoretical and experimental
interest because they challenge the notion that only nucleic acids are able to transmit heritable
information. But they are also of critical practical importance, since some of them are associ-
ated with devastating neurodegenerative diseases. In particular, the mammalian PrPSc (prion
protein, “scrapie” isoform) is the causal agent of the fatal transmissible spongiform encepha-
lopathies (TSEs) [2–4]. TSEs affect both humans and agriculturally important animals, and
while PrPSc prions typically remain contained within a given species, transmission of bovine
PrPSc to humans occurred in the aftermath of the massive European bovine spongiform
encephalopathy epizootic, killing more than 200 people and generating widespread alarm [5,
6]. Fortunately, through the intervention of regulators, the crisis has largely abated, although
transmission of CJD through blood transfusion remains a concern [5]. This leaves only spo-
radic Creutzfeldt-Jakob disease (CJD), a rare ailment with a yearly incidence of ~1 case per
million people, as the main human prion disease [2, 3].
Elucidating the molecular mechanism that governs the propagation of PrPSc, including
the aforementioned transmission barriers has been a central issue and a challenge in prion
research since these agents were first discovered [1]. This endeavor has been linked to the
quest to elucidate the structure of PrPSc, an obvious pre-requisite to understand how such con-
formation propagates, i.e, how it is copied.
In this respect, it is important to note that most known prions, and in particular, PrPSc,
form amyloids [4, 7–9]. Therefore, the main force driving and modulating prion propagation
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must be templating of an incoming partially or totally unfolded prion precursor protein mole-
cule by the upper and lower surfaces of the amyloid fiber. These contain “sticky” β-strands
ready to form an array of hydrogen bonds and thereby induce the formation of a new β-
strand-rich layer, thus promoting growth of the amyloid filament in the direction of its axis. A
recent cryo-electron microscopy study has determined the outline of the architecture of GPI-
anchorless PrPSc, showing that it is a 4-rung β-solenoid [10]. This agrees with prior fiber X-ray
diffraction [11, 12], 2D electron crystallography [11, 13] and SAXS-based [14] studies of other
brain-derived wild type (wt) PrPSc molecules leading to a similar conclusion. On the other
hand, another recent study has shown that shorter PrP sequences, such as PrP23-144, can
adopt a flat, in-register amyloid architecture which is also infectious [15].
During propagation of multi-rung β-solenoidal structure, only the upper and lower rungs
participate in inter-molecular hydrogen bonding. Identifying the specific amino acid residues
that participate in β-strands, in particular those that make up the templating interfaces is
essential to understand the details of PrPSc propagation, and, critically, to understand trans-
mission barriers.
In the past, we have used limited proteolysis to probe PrPSc, in an attempt to identify
sequential stretches that comprise β-strands vs. those that constitute the random coil loops/
turns of PrPSc. It should be noted that, in contrast with early hypotheses, the elegant studies of
the Surewicz and Caughey groups [16, 17] demonstrated that no α-helical secondary structure
is likely to exist in PrPSc. Data from deuterium/hydrogen exchange studies, and limited prote-
olysis experiments are incompatible with the presence of any substantial amount of α-helical
structure, and a critical reassessment of FTIR studies strongly suggests that absorbance peaks
ascribed to α-helices is likely to have been a mis-assignment [9].
Using two analytical approaches, high resolution SDS-PAGE combined with epitope analy-
sis, and mass spectrometry, we identified positions ~116/118, 133–134, 141, 152–153, 162, 169
and 179 (murine numbering) as PK cleavage sites in brain-derived PrPSc. These sites likely
define loops and/or borders of β-strands, and are helping us to define the hypothetical thread-
ing of the β-solenoid [18].
In this context, recPrPSc is a very attractive tool for structural studies, given that it allows
the introduction of the sequence variations, labels and isotopically labeled amino acid residues
necessary for rigorous NMR studies. A number of recombinant PrP preparations with differ-
ent degrees of infectivity have been described since the seminal report by Legname et al.[19–
22]. Recently, Wang et al. generated recPrPSc exhibiting incubation times similar to those of
brain-derived PrPSc of the same sequence and causing the same pathogenic changes as that of
wt prion disease [23, 24]. While incubation times should be considered very cautiously, given
that a long incubation time can be the result of low titer but also of a transmission barrier,
the study by Wang et al. has led to the definitive acceptance that bona fide, highly infectious
recPrPSc can be generated in vitro. As a corollary, the possibility to use the versatile recPrPSc as
a convenient model for elucidation of the structure of PrPSc in general was opened.
Here, we report studies to probe the structure of infectious recPrPSc using limited proteolysis.
Mouse and bank vole (Myodes glareolus) recPrPSc prions yield an array of N-terminally trun-
cated PK-resistant fragments very similar to that seen after PK treatment of brain-derived PrPSc.
This is strongly supportive of shared key architectural elements between both prion types.
Materials and methods
Reagents and antibodies
The following reagents were obtained from the indicated commercial sources: PNGase F, from
New England Biolabs (Ipswich, MA, USA); Tris/Tricine electrophoresis buffer and Broad-
RecPrPSc and PrPSc share a common architecture
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Range SDS-PAGE Standards from BioRad (Hercules, CA, USA); Sypro Ruby dye, and Novex
Sharp Pre-stained Portein Standard, from Thermo-Fisher (Whaltman, MA, USA); Immobilon
P 0,45 μm PVDF membranes, from Millipore (Billerica, MA, USA); Ultra-low Range Molecu-
lar Weight Marker, Pefabloc, PMSF and PK, from Sigma-Aldrich (St Louis, MO, USA). All
other reagents were from Sigma-Aldrich unless otherwise indicated.
Antibody R1, which recognizes PrP epitope 225–230 [25], was a generous gift from Anna
Serban, Institute for Neurodegenerative Diseases, UCSF, and was used at a 1:5000 dilution;
antibody #51, which recognizes PrP epitope 92–100 [26] was kindly provided by Lothar Stitz,
Fridrich Loeffler Institut, Insel Reims, Germany, and was used undiluted; antibody 3F10,
which recognizes PrP epitope 137–151 [27] was a generous gift from Yong-Sun Kim, Hallym
University, Republic of Korea, and was used at a 1:5000 dilution. Antibody SAF-84, which rec-
ognizes PrP epitope 165–172, was from Thermo Fisher Scientific (Rockford, IL, USA), and as
used at a 1:5000 dilution. Secondary antibodies were goat anti-human (Thermo Fisher) and
goat anti-mouse (GE Healthcare Life Science, Chicago, IL. USA), used to detect R1, 3F10 and
#51, respectively; both were used at a 1:5000 dilution.
Generation of recPrP
Recombinant mouse PrP23-230 (MoPrP23-230) was expressed in E. coli competent cells. Bac-
teria were harvested by centrifugation at 5.000 g. Bacterial pellets were lysed by incubation for
30 minutes at room temperature with shaking in lysis buffer (50mM Tris-HCl, 5mM EDTA,
1% Triton X-100, 1mM PMSF, 100 μg/ ml lysozyme, pH = 8); MgCl2 and DNase I were then
added to 20mM and 5μg/ml final concentrations, respectively, and further incubation at room
temperature carried out for 30 minutes. Inclusion bodies thus obtained were collected by cen-
trifugation at 20.000 g at 4˚C for 20 minutes, and solubilized with inclusion body solubilization
solution (6M Gn/HCl, 10 mM of Tris-HCl, 100 mM Na2HPO4 and 10 mM β-mercaptoetha-
nol, pH = 8.0). The solubilized sample was then filtered through a 0.22 μm filter and loaded
to a 5 ml FF Crude His-Trap column (GE Healthcare, Life Sciences (Chicago, IL. USA) con-
nected to a 1200 Series HPLC system (Agilent Technology, Santa Clara, CA, USA). The col-
umn was washed with inclusion body solubilization solution and refolded in-column by
gradually diminishing the concentration of Gn/HCl and β-mercaptoethanol with a gradient of
10 mM of Tris-HCl, 100 mM Na2HPO4, pH = 8.0 over 100 minutes; recMoPrP23-230 was
then eluted with 30 ml of 200 mM imidazole in10 mM Tris-HCl, 100 mM Na3PO4,pH = 8.0).
The eluate was dialyzed against10mM NaH2PO4, pH = 5.8, and subsequently against d.i. H2O
at 4˚C. Dialyzed samples were centrifuged to eliminate any aggregated material present and
stored at -80˚C until used for conversion to recPrPSc.
Bank vole PrP23-231 (BVPrP23-231) was expressed following the same protocol, and
similarly applied to a His-Trap column as described above; however, it was eluted from the col-
umn by application of a solution consisting of 10 mM Tris-HCl, 2M Gn/HCl, and 100 mM
Na2HPO4, pH = 8.0. Elution fractions containing PrP, as determined by SDS-PAGE with Coo-
massie staining, were then folded by dialysis against 10 mM sodium acetate, pH = 5. Precipi-
tated material was removed by centrifugation.
Generation of recPrPSc
Two preparations of recombinant (rec) murine PK-resistant (PK-res) PrP and one of recombi-
nant bank vole PK-res PrP were analyzed in this study; all of them were prepared using differ-
ent variants of recombinant PMCA (recPMCA). Recombinant MoPrPSc-17kDa was prepared
in Grand Rapids (USA) and has been described before [23]. Briefly, it was generated de novo
RecPrPSc and PrPSc share a common architecture
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006797 January 31, 2018 4 / 21
from recMoPrP23-230 by recPMCA in the presence of POPG and RNA and its infectivity has
been tested in WT mice resulting a 100% attack rate [23, 24].
A recMoPrPSc (vide infra with regard to its infectivity properties) was generated in Bilbao,
Spain, from recMoPrP23-230 expressed, purified and folded as described above, by means of
recPMCA seeded with recMoPrPSc-17kDa in the presence of 1-palmitoyl-2-oleoyl-sn-glycero-
3-phosphoglycerol (POPG) and RNA [23, 24]. This sample was termed recMoPrPSc-950.
A sample of recBVPrPSc (vide infra) was prepared by seeded recPMCA using a protocol that
will be detailed elsewhere. Briefly, recBVPrP23-231 (109I) prepared, purified and folded as
described above, was used as a substrate in a mixture that contains dextran and detergent and
that was subjected to several cycles of PMCA; the initial seed used was a small portion of brain
homogenate from a bank vole (109I) infected with deer CWD prions.
Animal studies
Ethics statement. Animal experiments were carried out in accordance with the European
Union Directive 86/609/EEC on Laboratory Animal Protection. In mouse experiments carried
out in Santiago de Compostela procedures and animal care were governed by a protocol that
was approved by the Institutional Ethics Committee of the University of Santiago de Compos-
tela (15005/16/006). For the experiments carried out in Rome, bank voles carrying isoleucine
at PRNP codon 109 [28] were obtained from the breeding colony at the Istituto Superiore di
Sanità. The research protocol, approved by the Service for Biotechnology and Animal Welfare
of the ISS and authorized by the Italian Ministry of Health (decree number 84/12.B), adhered
to the guidelines contained in the Italian Legislative Decree 116/92, which transposed the
European Directive 86/609/EEC on Laboratory Animal Protection, and then in the Legislative
Decree 26/2014, which transposed the European Directive 2010/63/UE on Laboratory Animal
Protection. All efforts were made to minimize animal suffering.
A total of 18 Tga20 mice were intracerebrally (ic) inoculated at 2–3 months of age with
20 μl of recMoPrPSc-950, and5 Tga20 mice were intracerebrally inoculated at the same age
with the same amount of recMoPrPSc17kDa. Ten eight-week old bank voles were intracere-
brally with 20 μl of a 10−1 dilution of PMCA misfolded rec-PrP into the left cerebral hemi-
sphere, under ketamine anaesthesia (ketamine 0.1 μg/g). All animals were individually
identified by a passive integrated transponder. The animals were examined twice a week until
neurological signs appeared, after which they were examined daily. Diseased animals were
humanely euthanized with carbon dioxide at the terminal stage of the disease, but before neu-
rological impairment was such as to compromise their welfare, in particular their ability to
drink and feed adequately. Survival time was calculated as the interval between inoculation
and euthanasia.
GPI-less PrPSc
Transgenic homozygous GPI-anchorless (GPI-) PrP mice (tg44-/-), were obtained by crossing
of tg44(+/-) heterozygous (GPI-) PrP mice [29], generously provided by Bruce Chesebro,
Rocky Mountain Laboratories, NIH, USA [26]. This GPI-anchorless tg mouse model is the
same that we have used in the past [26]; additional GPI-anchorless tg mouse models have been
developed [30]. Female mice were inoculated ic at six weeks of age with 20 μl of a 2% RML-
infected mouse brain homogenate, kindly provided by Juan Marı´a Torres, CISA, Madrid,
Spain. After 365 days post inoculation, mice were euthanized, their brains surgically removed,
rinsed in PBS, and stored at -80 ˚C until needed. A 10% w/v, brain homogenate was prepared
in PBS, 5% sarkosyl, using a dounce homogenizer (Wheaton Industries Inc, NJ, USA), fol-
lowed by one pulse of sonication to clarify the homogenate, with an ultrasonic homogenizer
RecPrPSc and PrPSc share a common architecture
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probe (Cole Parmer Instrument CO., Chicago IL, USA). The brain homogenate was treated
with 25μg/ml of PK for 30 minutes at 37˚C, and then deglycosylated with PNGase F following
the manufacturer´s recommendations.
Limited proteolysis
RecMoPrPSc was treated with 10 μg/ml PK, at 37˚C for 30 minutes. The reaction was quenched
by adding 2 mM Pefabloc and incubated for 15 minutes on ice. PK-resistant fragments were
then pelleted by centrifugation at 18.000 g at 4˚C for 1 hour using a (Microfuge 22R centrifuge,
Beckman Coulter). Under these conditions, all PK-resistant fragments are recovered in the
pellet (S1 Fig). Pellets were resuspended in 6M Gn/HCl and stored at -20˚C until use.
Electrophoresis, western blotting and epitope analysis
PK-resistant fragments were precipitated with ice-cold 85% MeOH. Pellets were resuspended
in MiliQ H2O and Tricine buffer in a ratio 1:2. Reduction was carried out by adding β-merca-
toethanol to 2% (v/v). Samples were boiled for 10 minutes. High resolution electrophoresis
was carried as described by Va´zquez-Ferna´ndez et al. [26]. After electrophoresis, gels were
washed with miliQ H2O and incubated with fixing solution (10% MeOH, 7% acetic acid) for 1
hour at room temperature. Sypro Ruby staining was then performed by incubation overnight
at room temperature in the darkness. Alternatively, the gels were transferred to Immobilon P
0.45 μm PVDF membranes, which were subsequently probed with the antibodies described
above.
Mass spectrometry
A 1μL sample of the solution of PK-resistant recPrPSc fragments solubilized in 6M Gnd/HCl
(vide supra) was mixed with 49 μL of sinapinic acid solution (10 μg/mL of sinapinic acid dis-
solved in 30% acetonitrile (ACN) with 0.3% trifluoroacetic acid (TFA) and analyzed by MAL-
DI-TOF. One half μL aliquots were deposited using the dried-droplet method onto a 384 Opti-
TOF MALDI plate (Applied Biosystems, Foster City, CA, USA). MALDI analysis was per-
formed in a 4800 MALDI-TOF/TOF analyzer (Applied Biosystems). MS spectra were acquired
in linear mode (20 kVsource) with a Nd:YAG, (355 nm) laser, and averaging 500 laser shots.
For spectra data analysis of recMoPrPSc samples, an initial external calibration was carried
out using insulin (m/z = 5733), ribonuclease A (m/z = 13682) and lysozyme (m/z = 14305),
(Sigma-Aldrich) as standards. A peak with m/z = 9390.2 Da, corresponding to fragment N153-
S230, was unambiguously identified with a mass error < 1 Da by ESI-TOF analysis (vide infra)
of the same sample (S2 Fig). This peak was used as an internal calibrant, and all m/z values in
the spectrum corrected accordingly. For recBVPrPSc samples, only external calibration was
used. The final resulting m/z values were matched to PrP fragments with the help of GPMAW
6.0 software (Lighthouse, Odense, Denmark). Final experimentally calculated mass data are
shown in Tables 1 and 2, and match theoretical values within the experimental error of the
MALDI-TOF analysis.
As indicated, 10 μl of PK-resistant recPrPSc were subjected to ESI-TOF analysis. The sample
was injected to an Agilent 1100 HPLC system equipped with a Vydac 218TP C-18 column
(Vydac, MD, USA). A gradient of ACN over 0.1% formic acid was applied over 60 minutes, at
a flow of 0.2 ml/min. The effluent of the column was fed into a Bruker Microtof Focus mass
spectrometer (Bruker Daltonik, Billerica, MA, USA) and sprayed into the mass detector. The
capillary voltage was set at 4500 V, the pressure of the nebulizer was 2.5 Bar, the drying gas
flow 8 L/minute and the drying temperature, 200 ˚C. The mass range of the detector was 50–
3000 m/z.
RecPrPSc and PrPSc share a common architecture
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Results
Generation of recMoPrPSc
Using seeded recPMCA, we generated a recMoPrP auto-propagative species that we termed
recMoPrPSc-950, and was partially resistant to PK (Fig 1A). In order to assess its infectivity,
and therefore its prionic nature, we performed animal bioassays. We inoculated this putative
recombinant murine prion, into the brains of 18 Tga20 mice. All 18 inoculated Tga20 mice
developed standard clinical signs of prion disease (ataxia, hindlimb paralysis, kyphosis, weight
loss) and were eventually euthanized (Fig 2A). Histopathological and immunohistochemical
examination of the brains of animals inoculated with PK-resistant MoPrP, showed characteris-
tic TSE spongiform lesions and PrPSc deposits, typical of prion disease (Fig 2B). Furthermore,
immunochemical analysis of brain homogenates revealed the presence of PK-resistant PrP
(Fig 2C). All this confirms that the inoculated material was a prion, and therefore it could be
appropriately referred to as recMoPrPSc-950. In this study we also analyzed a preparation of
the recombinant murine prion recMoPrPSc-17kDa [23–24]. Although its infectious nature
had already been established [23, 24], we confirmed it under our experimental conditions. We
inoculated a group of 5 Tga20 mice, all of which developed signs of prion disease and were
humanely euthanized after 119 ± 20 days. Immunohistochemical and immunochemical analy-
sis of brains confirmed prion disease, in agreement with previous published studies [23, 24]
Structural characterization of recMoPrPSc using limited proteolysis
We subjected recMoPrPSc-950 and recMoPrPSc-17kDa to limited proteolysis using 10 μg/ml
of PK for 30 minutes at 37 ˚C. PK-resistant fragments were detected by Sypro Ruby staining
Table 1. MALDI analysis of PK-resistant fragments in recMoPrPSc-950.
recMoPrPSc-950
Observed mass (MALDI)
(kDa)
Theoretical mass
(kDa)
Sequence Corresponding
WB bands
Equivalent PK-resistant fragment(s) in GPI-anchorless PrPSc
13441.1 13431.0 A116-S230 ~14.6 kDa A116/G118- S232

11871,3 11867.1 S134-S230 ~13 kDa M133/S134—S232
11391,9 11395.6 I138-S230 ~12 kDa G141—S232
10997.2 11998.1 G141-S230 ~12 kDa G141-S232
9514.1 9513.6 N152-S230 ~10.2 kDa N152—S232
9399.5♦ 9399.5 M153-S230 ~10.2 kDa M153-S232
8187.9 8184.1 Y162-S230 ~8 kDa Y162-S232
6097.7 6103.9 V179-S230 ~6.7 kDa V179-S232
(GPI-) PrP mice (tg44-/-) express PrP with a sequence that includes two extra serine residues at its C-terminus ([26]).
♦Exact value obtained from ESI-TOF analysis (see Materials and methods) and used for internal calibration of MALDI-TOF data.
https://doi.org/10.1371/journal.ppat.1006797.t001
Table 2. MALDI analysis of PK-resistant fragments in recBVPrPSc.
recBVPrPSc
Observed mass (MALDI)
(kDa)
Theoretical mass
(kDa)
Sequence Corresponding Coomassie band number Equivalent PK-resistant fragment in GPI-anchorless PrPSc
13364 13353.4 A117-S231 2 A116/G118- S232
11979 11992.3 A133-S231 3 M133/S134—S232
11789 11790.0 S135-S231 3 M133/S134—S232
9436 9436.4 N153-S231 4 N152—S232
https://doi.org/10.1371/journal.ppat.1006797.t002
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after SDS-PAGE. In recPrPSc-17kDa, a clear, intense ~17 kDa fragment was readily apparent,
with two additional somewhat fainter and broader bands, one of ~6.5 kDa, and another with a
MW between 6.5 and 3.5 kDa (Fig 3A, left). The ~17 kDa band is obviously equivalent to the
classic PrP27-30 PK-resistant fragment seen in brain-derived samples, which migrates between
27–30 kDa [1, 3, 16, 26]. Both PK treated recMoPrPSc-17kDa and PrP27-30 lack amino acids
23–90, so the difference in migration between the two molecules is due to the lack of a GPI
anchor and lack of glycosylation in the PK-treated recMoPrPSc-17kDa. This 17kDa epony-
mous fragment has been previously reported for recMoPrPSc-17kDa [23]. The lower MW PK-
resistant fragments may have been previously overlooked, since they would run near the front
in conventional SDS-PAGE systems.
In PK treated recMoPrPSc-950 a ~16 kDa band was conspicuous. Additional PK-resistant
fragments with smaller apparent MWs between ~15 and ~3.5 kDa, several of them with an
intensity similar to that of the uppermost ~16 kDa fragment, were also detected (Fig 3A,
right). Compared to the pattern obtained from recPrPSc-17kDa, a number of intense bands in
Fig 1. Generation of recPrPSc in vitro using recPMCA: rec-PrPSc propagate its conformation in vitro. A) A misfolded, propagative
mouse PrP species (rec-MoPrPSc-950) was generated in the presence of lipids and RNA[23]using RecMo-PrPSc-17KDa, generated in
Grand Rapids (MI, USA), as seed in a recPMCA reaction. The seed was diluted 1:10 in each round of recPMCA up to 17 rounds and the
resulting product was digested with 10 μg/ml of PK. The final product is termed “Sc” as its infectivity in vivo was later confirmed (Fig 2).
B) A misfolded, propagative bank vole PrP species (recBVPrPSc) was generated utilizing a different version of seeded recPMCA (details to
be described elsewhere), using recBVPrP23-231 PrP as a substrate. Twenty five rounds were completed. The resulting product was
digested with 85 μg/ml of PK. The final sample is termed “Sc” as its infectivity in vivo was later confirmed (see Results section). Both
samples were analyzed by Western blot using monoclonal antibody Saf83 (1:400). Undigested bank vole and mouse rec-PrP were used as
control. MW: molecular weight markers. In A, central lanes with irrelevant samples have been removed from the image for clarity.
https://doi.org/10.1371/journal.ppat.1006797.g001
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the 15–10 kDa range were seen in recMoPrPSc-950 that were extremely faint or altogether
absent in recPrPSc-17kDa (Fig 3A).
We used a set of monoclonal antibodies with well characterized linear PrP epitopes to per-
form epitope mapping of the PK-resistant fragments present in our samples. We used antibod-
ies recognizing “N-terminal” (antibody #51: 92–100), central (antibody 3F10: 137–151) and C-
terminal (antibody R1: 225–230) epitopes. The 92–100 epitope is considered here “N-termi-
nal” given the total absence of any PK-resistant species containing the ~23–90 amino-terminal
stretch, believed to be flexible in all PrP conformers. Therefore, position ~90 is considered,
for simplicity, to be the reference “amino terminus” of PK-treated samples. The amino acid
sequences of mouse and bank vole PrP are shown in S3 Fig to facilitate evaluation of the
results.
Fig 2. Characterization of the infectivity of recPrPSc. A) Kaplan-Meier survival plots of Tga20 mice inoculated with
recMoPrPSc. B) Histopathological and immunohistochemical analysis of brains fromTga20 mice inoculated with
recMoPrPSc and uninoculated tga20 controls: left: haematoxylin-eosin (H&E) staining of the medulla oblongata, notice
the spongiform lesion in the inoculated mice (bottom); right: PrPSc IHC staining (antibody 2G11, epitope: 151–159) of
the medulla oblongata showing fine granular PrPSc deposits in the inoculated mice (bottom). C) WB showing the
presence of PK-resistant PrP in the brains of Tga20 mice inoculated with recMoPrPSc.
https://doi.org/10.1371/journal.ppat.1006797.g002
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The use of a high resolution Tris/Tricine SDS-PAGE system optimized the separation of
PK-resistant fragments, particularly the smaller ones, while allowing us to compare their pat-
tern with that of PK-treated GPI-anchorless PrPSc, previously analyzed by our group [26].
These results are shown in Fig 3B–3D, which shows results in the following order: “N-termi-
nal”, central and C-terminal antibodies.
The “N-terminal” antibody, #51 (epitope 92–100), detected the ~17 and ~16 kDa bands
stained by Sypro ruby in gels corresponding to recPrPSc-17kDa and recMoPrPSc-950, respec-
tively (Fig 3B). In agreement with previous studies [26], antibody #51 recognized the pre-
dominant ~17 kDa PK-resistant band in a GPI-anchorless PrPSc-containing sample, which
corresponds to (81/89-232) (Fig 3B left); it should be mentioned that GPI-anchorless PrP
contains two extra C-terminal amino acid residues as a consequence of the way in which the
transgene was designed [26].
Fig 3. Comparison of PK-resistant fragments from recMoPrPSc vs. brain-derived, GPI-anchorless PrPSc. Recombinant
MoPrPSc-950 were treated with PK (see main text for more details)A) Sypro ruby-stained SDS-PAGE gels of recMoPrPSc-950,
andrecPrPSc-17kDa. Alternatively, gels were blotted onto PVDF membranes and probed with antibodies: B) #51 (epitope 92–
100); C) R1 (epitope 225–230); or D) 3F10 (epitope137-151). WBs are representative of several experiments (a minimum of 3 for
each antibody).
https://doi.org/10.1371/journal.ppat.1006797.g003
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Considering their apparent sizes, the ~17 and ~16 kDa PK-resistant fragments in the
recPrPSc-17kDa and recMoPrPSc-950 samples (Fig 3B) must correspond to partially overlap-
ping collections of PK-resistant fragments with “ragged termini” [31, 32], with a predomi-
nance of cleavages around positions ~86–89 in recPrPSc-17kDa, and 92–98 in recMoPrPSc-
950. This difference is reminiscent of the difference between Drowsy vs. Hyper or CJD type I
vs. type II major PK-resistant PrPSc fragments [31, 32].
The recMoPrPSc-950 sample also contained a broad ~5–7 kDa band, absent in recMoPrPSc-
17kDa (Fig 3B center). Considering its apparent MW, it can be concluded that this band neces-
sarily corresponds to doubly N- and C-truncated PK-resistant fragments.
Antibody R1, which recognizes the C-terminal epitope (225–230) detected, as expected, the
~17 and ~16 kDa PK-resistant fragments also seen using Sypro Ruby and antibody #51, in
GPI-anchorless PrPSc, recPrPSc-17kDa, and in recMoPrPSc-950, respectively, supporting the
notion that these fragments span from ragged ends beginning around position G92 all the way
to the C-terminus (Fig 3C). In the GPI-anchorless sample, R1 detected, besides, the 6 addi-
tional bands previously described and characterized by Va´zquez-Ferna´ndez et al. [26] (Fig 3C
left). Remarkably, the pattern of bands detected by this antibody was, to a considerable extent,
similar in the other two infectious prion samples, i.e., recMoPrPSc-17kDa and recMoPrPSc-
950. Namely, the ~14.6, ~13, ~12,~10.2, 8, and ~6.7 kDa bands described by Va´zquez-Ferna´n-
dez in GPI-anchorless PrPSc [26] were seen in the GPI-anchorless PrPSc, recMoPrPSc-17kDa
and recMoPrPSc-950 samples, although the relative intensities of bands varied from sample to
sample (Fig 3C). Considering the extreme C-terminal position of the R1 epitope, which leaves
virtually no leeway for alternative sequence combinations leading to a given apparent MW, we
can tentatively conclude that there might be a very close identity of these bands between the
three samples, which in turn means that cleavage sites are approximately the same. On the
other hand, there was one evident difference in the PK digestion pattern of recMoPrPSc-950
with respect to the recMoPrPSc-17kDa and GPI-anchorless samples: two bands, with apparent
MWs of ~4.5 and ~3.5 kDa, which are absent in the other samples (Fig 3C). Considering their
sizes, they should correspond to novel PK-resistant fragments with N-termini around~G194
and ~E206, respectively.
The central antibody 3F10 (epitope 137–151) should recognize the ~17/16, ~14.6, ~13 and
perhaps the ~12 kDa bands recognized by R1 (Fig 3C), given that they also contain the epitope
recognized by 3F10: these bands correspond to fragments ~92/98-230,~116–230, ~134–230
and ~138–230, respectively [26]. Indeed, the antibody revealed bands of these sizes in the two
prion samples, albeit with different relative intensities (Fig 3D). Antibody 3F10 also detected
additional fragments of ~10, ~8, ~7 and ~6 kDa in the recombinant samples that were not
present in GPI-anchorless PrPSc. More specifically, the ~10 kDa band was seen in both sam-
ples, while the others were seen in recMoPrPSc-950 (Fig 3D). None of these bands coincides
with those recognized by R1 (compare Fig 3D with Fig 3C), whether they have or have not the
same size, as there is no possible overlap of epitopes for fragments smaller than 12 kDa. Thus,
fragments ~152–230, ~162–230 and ~169/179-230, lack the 3F10 epitope. Therefore, the ~10,
~8, ~7, and ~6 kDa fragments recognized by 3F10 must necessarily correspond to doubly N-
and C-terminally truncated PK-resistant fragments. Some of these fragments, more specifically
some of those seen in the recMoPrPSc-950 sample, also contain the (92–100) epitope recog-
nized by antibody #51 (Fig 3A), while others do not, and therefore their N-termini must lie
beyond the 92–100 sequence. In summary, the combined mapping reveals the existence of a
number of PK-resistant fragments with a double truncation at both the N- and C-termini.
These fragments are particularly prevalent in recMoPrPSc-950, with N-termini, in this case,
around~G92. These N-,C-truncated fragments were not seen in PK-treated GPI-anchorless
PrPSc (Fig 3D left), in agreement with previous results [26].
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We further probed the PK-resistant fragments in PK-treated recMoPrPSc-950 with an addi-
tional antibody, SAF-84 (epitope: 166–172, located between those recognized by 3F10 and R1).
Results were consistent with the patterns revealed by these two antibodies and are described in
detail in S4 Fig.
We sought to confirm the identity of PK-resistant bands in our recombinant samples,
approximately revealed by the sizes and pattern of bands surmised from epitope analysis,
by means of mass spectrometry. For logistical reasons, we could only obtain data from
recMoPrPSc-950. As shown in Fig 4, Table 1, and S2 Fig, MALDI and ESI-TOF analysis of the
same sample identified a number of C-terminal peptides PK-resistant peptides, namely, 89–
230, 97–230, 116–230, 134–230, 138–230, 141–230, 152–230, 153–230, 162–230 and 179–230.
Such peptides coincide quite well with the apparent MWs of C-terminal peptides detected by
antibody R1 (Table 1). Also, in agreement with results obtained with epitope analysis, these
peptides are equivalent to those obtained after PK treatment of GPI-anchorless PrPSc [26].
Fig 4. MALDI analysis of PK-resistant fragments from recMoPrPSc. A) MALDI spectrum of recMoPrPSc-950 digested with PK (for more details see the main
text). Peak identities were assigned using GPMaw (see text for details). The horizontal line indicates unassigned peaks perhaps corresponding to N-,C- doubly
truncated fragments. The asterisk marks poorly defined peaks corresponding to fragments with ragged N-termini beginning at positions ~92–98. B)Scheme
showing the location of PK cleavage sites (in red) in the context of the map of PK cleavage sites in GPI-anchorless MoPrPSc obtained by Va´zquez-Ferna´ndez
et al. (in blue, [26]); colored triangles indicate the approximate position of the epitopes of antibodies #51, 3F10 and R1.
https://doi.org/10.1371/journal.ppat.1006797.g004
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Generation and characterization of recBVPrPSc
We also generated a recBVPrP auto-propagative species that was partially resistant to PK (Fig
1B). To confirm its infectious, prionic nature, we inoculated this putative recBVPrPSc into the
brains of a group of 10 bank voles expressing homozygous PrP (109I) [33]. Eight of ten bank
voles inoculated with putative recBVPrPSc succumbed to prion disease with a mean survival
time of 239 ± 49 days post-inoculation, while the other 2 died of inter-current causes at an
early age (206 days post-inoculation), and therefore it cannot be concluded whether they were
developing a prion disease or not. Histopathology of brains of these animals confirmed prion
disease (S5 Fig). Full details of this prion disease has been reported elsewhere [34]. Therefore,
the inoculated material is also a prion and can be appropriately referred to as recBVPrPSc.
Treatment of recBVPrPSc with 20 μg/ml of PK resulted in the appearance of a number of PK-
resistant fragments, as seen after Coomassie staining (Fig 5). A doublet of closely migrating
~17 kDa fragments was predominant. We reasoned that it might correspond to the entire PrP
sequence minus the extremely flexible ~23–89 tail (Bank vole numbering), with two close but
slightly different N-terminal cleavage patterns, i.e., the equivalent of the ~17 kDa band of GPI-
anchorless PrPSc. These two bands were excised and subjected to in-gel tryptic digestion.
MALDI analysis of the digest led to the detection of a number of tryptic peptides from amino-
terminal (H111-R136), central (P137-R148) and carboxy-terminal (E221-R229) regions of PrP (con-
sidering the expected loss of the extreme amino-terminal flexible tail, up to ~G90, in fact
Fig 5. Analysis of PK-resistant fragments of recBVPrPSc. A) Coomassie-stained SDS-PAGE of recBVPrPSc treated with PK (see text for more details); numbered
bands were excised, digested with trypsin in gel and analyzed as described in the Materials and Methods section. B) MALDI spectrum of the same PK-treated sample;
the horizontal line in B indicates unassigned peaks perhaps corresponding to N-,C- doubly truncated fragments.
https://doi.org/10.1371/journal.ppat.1006797.g005
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confirmed by the complete absence of peptides from that region). A characteristic peak with
m/z of 1820 Da, corresponding to a “ragged end” tryptic peptide G90-K106 [35]was also seen in
both samples (S6 Fig). No obvious differences in the spectra from the two bands were identi-
fied. Since an obvious possibility was the slight difference in apparent MW between the two
bands might be the result of different ragged termini, a thorough search for peaks correspond-
ing to tryptic peptides with different ragged termini was carried out, but yielded no obvious
differences between the two bands. Therefore, the nature of the difference between the two
bands cannot be explained at this point.
In addition to this doublet, at least three additional PK-resistant fragments were detected in
the Coomassie-stained SDS-PAGE gel (Fig 5). These lower bands were also subjected to in-gel
tryptic digestion followed by MALDI-TOF analysis of the resulting tryptic fragments; MALDI
spectra (S6 Fig) showed signals corresponding to tryptic fragments of different regions of the
BVPrP sequence, in different proportions, confirming that these bands are PrP fragments of
different sizes. In parallel, direct MALDI analysis of the sample confirmed the presence of frag-
ments with sequences 153–231, 135–231, 133–231, 117–231, 75/83-231, and 83/90-231 (Fig 5
and Table 2). A group of peaks corresponding to peptides with masses between ~7000 and
~8000 Da was also evident (Fig 5 and Table 2); these might correspond to doubly N- and C-
terminally truncated PK-resistant peptides, similar to those seen in the recMoPrPSc samples,
although this cannot be confirmed at this time.
Discussion
Recombinant PrPSc will become an invaluable tool for prion structural studies. Recombinant
PrPSc is produced by converting bacterially derived PrP into recPrPSc, which means that incor-
poration of stable isotopes or different natural or unnatural amino acids into PrP sequences is
greatly simplified. This will allow researchers to prepare custom-made recPrPSc for NMR-
based analyses. However, it will be critical for these efforts to use fully infectious recPrPSc sam-
ples. To date, reports have described studies of amyloid recombinant PrP preparations exhibit-
ing very limited infectivity [36, 37], known to have a structure different to that of PrPSc. On the
other hand, very rich structural information is being extracted from highly infectious PrP23-
144 amyloid fibers, revealing a flat in-register cross-β stack [15, 38] that is also different from
the 4-rung β-solenoid that characterizes full length PrPSc [10].
Our recPrPSc prions, made in vitro from bacterially derived recombinant PrP, exhibit full
infectivity, with attack rates of 100% and incubation periods comparable to wt prions. They
share key architectural features with brain-derived PrPSc, when analyzed by a limited proteoly-
sis-based structural analysis [26, 39, 40]. Limited proteolysis of these recPrPSc species gener-
ated a fragmentation pattern consisting of a number of PK-resistant fragments that were the
same as or equivalent to those obtained during limited proteolysis of GPI-anchorless MoPrPSc
and wt SHaPrPSc. In particular, mass spectrometry-based analysis revealed nicks at positions
89/90, 116/18, 133/134, 141, 152/153, 162 and 179 (Table 1), in excellent agreement with con-
clusions derived from epitope analysis (Fig 3).
A group of doubly truncated fragments were much more conspicuous in recMoPrPSc-950
than recMoPrPSc-17kDa. Their exact sequence remains uncertain. However, one of the frag-
ments from recMoPrPSc-950 clearly spans the sequence comprising the epitopes of antibodies
#51 and 3F10. This result is consistent with a fragment from positions ~89–152. Such a frag-
ment would complement the fragment spanning the sequence 153–231 see in PK treated
recMoPrPSc-950 and GPI-anchorless PrPSc. The theoretical MW of such a fragment would be
6.7 kDa, in good agreement with the band recognized by antibody #51 (Fig 3B). The existence
of three distinct bands recognized by 3F10 indicates additional cleavage sites between ~89 and
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~152. Based on the analysis of other prions, candidates for these N-terminal cleavage sites are
~117/119 and ~134. Such fragments would be recognized by 3F10 but not #51. For the previ-
ously stated reasons, we are unable to define the precise sequences of these peptides. Further-
more, the different responses of different antibodies complicate interpretation of the data.
Thus, the ~6.5 kDa fragments detected by 3F10 in recMoPrPSc-17kDa seem not to contain the
(92–100) epitope, but in the absence of additional information, it is difficult to conclude where
exactly their termini are located.
Doubly truncated fragments have not been associated with the majority of “classical” brain
derived prions, such as GPI-anchorless PrPSc [26], scrapie MoPrPSc, 263K and Dy SHaPrPSc
[39], or CJD PrPSc [41]. In contrast, low MW bands corresponding to doubly truncated PK-
resistant fragments are hallmarks of “atypical” PrPSc strains, including Gertsmann-Streussler-
Scheinker (GSS)-PrPSc, and atypical scrapie-OvPrPSc strains, such as Nor98 PrPSc [40, 42].
Thus, analysis of brain homogenates from GSSP102L patients showed the presence of two PK-
resistant PrP fragments with apparent molecular masses of ~21 and ~8 kDa. The ~21 kDa frag-
ment, similar to the PrP-res type 1 described in CJD (i.e., the classic triad of PrP27-30 frag-
ments with variable glycosylation), is typically found in some cases, whereas the ~8 kDa
fragment is found in all cases, and has been taken to represent a pathognomonic characteristic
of GSS [31, 43]. However, a similar PK-resistant fragment has been also detected in bank vole-
adapted CJD PrPSc, blurring to some extent the distinction between classic and atypical strains
of PrPSc [41]. Mass spectrometry-based analysis of the GSS ~8 kDa fragment revealed that it
consists of a collection of peptides with ragged termini, spanning from 74/78/80/82 to 147/
150/151/152/153 [43]. Furthermore, the ~7 kDa PK-resistant fragment of PrPSc detected in
A117V GSS cases was seen, using mass spectrometry analysis, to span from Gly88/Gly90 to
Arg148/Glu152/Asn153 [44].
As shown by Pirisinu et al., this pattern is remarkably similar to that of Nor98 atypical
PrPSc, treatment of which with PK yields a ~7 kDa resistant fragment whose sequence is 71/
79-153 [40]. In contrast, the most resistant part of PrPSc from classical strains is, precisely, the
complementary sequence: a 152/153-232 fragment becomes prevalent with increasing treat-
ment time with PK of GPI-anchorless PrPSc [26], and remains folded upon guanidine-induced
partial unfolding [26, 45]. All of this suggests that the region around 152/153 marks a “hinge”
that connects two stable sub-domains within PrPSc. It is noteworthy that this region signals
two halves of the putatively folded region of PrPSc of comparable size; since the flexible loop
likely spans to P157 (murine numbering), it would connect two sub-domains of~62 and ~72
residues spanning N- and C-terminally with respect to it.,Higher resistance of either the ~152/
153-230 half, typical of “classical” PrPSc strains [26, 39, 45] (but vide supra) or of the ~80/90-
152/153 half, characteristic of “atypical strains” [31, 40, 43, 46] might reflect differences in the
threading within these specific sub-domains, with differences in the relative content in β-sheet
secondary structure (longer or shorter β strands) and packing of the loops connecting them.
However, the fact that overall similar nicks are detected in all cases suggests that threading dif-
ferences are not very large, and that overall, the same elements of secondary structure, likely
arranged in the same way, are characteristic of the structures of all three classes of PrPSc. It
should also be noted that in any given PrPSc prion isolate, including our recombinant ones,
there might exist mixtures of more than one structure. In that case, the relative abundance
of specific PK-resistant fragments will reflect the relative contributions of such structural
variants.
Our study also provides preliminary evidence, in recMoPrPSc-950, of two additional, C-ter-
minally located, PK cleavage sites not previously detected in brain-derived PrPSc. The strongest
evidence of the existence of such cleavage sites was provided by a ~4.5 kDa band in the Sypro
Ruby stained gel of recMoPrPSc (Fig 3A). A band with a similar apparent MW detected by the
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C-terminal antibody R1 (epitope 225–230), and since no similar size bands detected by either
#51 (epitope 92–100) or 3F10 (epitope 137–151), it follows that there is a PK-resistant frag-
ment spanning from a position around G194 to the C-terminus. Furthermore, a band detected
by R1 (225–230), with an apparent MW of ~3.5, suggests the existence of a second C-terminal
PK-resistant fragment, starting around position E206 and spanning to the C-terminus. The
absence of a clear equivalent band in the Sypro Ruby-stained gel suggests that the relative
abundance of this fragment might be small. Recently, we started to elaborate a generic thread-
ing model of PrPSc by distributing PK-cleavage sites, proline residues and other known struc-
tural constraints into a 4-rung solenoid [18]. A cleavage site at G194 is compatible with the
predicted starting point of the lowermost (C-terminal) rung. However, definitive proof of the
identity of these cleavage points should await confirmation by mass spectrometry. Further-
more, given that these cleavage sites have not been detected in GPI-anchorless PrPSc, it
remains to be seen whether they are or not a general feature of the architecture of PrPSc.
Ours is not the first structural study of recPrPSc. Recently, Noble et al. probed the structure
of an infectious recPrPSc sample by deuterium/hydrogen exchange followed by pepsin diges-
tion and mass spectrometric analysis [47]. They found very substantial protection (i.e., resis-
tance to exchange) in a stretch spanning from position ~89 up to the C-terminus, suggestive of
a β-sheet-rich secondary structure. Short stretches exhibiting somewhat lower protection sug-
gest the presence of loops/turns. In particular, the R150-Y154 stretch stands out as the possible
location of a loop. The furthermost C-terminal stretch Y224-S230 also shows slightly decreased
protection. These results are very similar to those reported by Smirnovas et al. in a similar
analysis of GPI-anchorless PrPSc [17]. These authors found substantial protection, indicative
of compact, β-sheet-rich structure, from G81 up to the C-terminus, with a lower protection
from Y224 to the C-terminus. These results support the notion that the structure of the recPrP
Sc
prepared by Noble et al. is similar to that of GPI-anchorless PrPSc, in agreement with the
results reported here. It should be noted that the pattern of exchange of a non-infectious
recPrP amyloid sample was very different, with low exchange rates seen only beyond position
~160 [17].
In summary, our studies show that several infectious mouse and bank vole recPrPSc, gener-
ated with the concourse of PMCA, exhibit biochemical properties that strongly suggest that
they share key architectural elements with brain-derived PrPSc. Furthermore at least in the
case of the mouse sample that we have obtained and studied, they seem to feature a mixture of
structural properties of “classical” and “atypical” strains of brain PrPSc, although they also
show some specific structural nuances. Therefore, we are convinced that such recPrPSc consti-
tute an excellent tool for future additional structural studies. It is noteworthy that cryoEM
images of our samples (S7 Fig) as expected, showed fibrils that are very similar to those seen in
brain-derived GPI-anchorless PrPSc samples. In summary, recPrPSc samples will be very useful
in future structural studies based on the use of NMR.
Supporting information
S1 Fig. PK-resistant fragments are recovered in the pellet after centrifugation at 18.000 g.
RecMoPrPSc-950 was treated with 10 μg/ml PK at 37 ˚C for 30 minutes; the reaction was ter-
minated by adding 2 mM Pefabloc. The sample was then centrifuged at 18.000g at 4 ˚C for 1 h.
The pellet (P) was resuspended in a volume of 6M Gn/HCl equal to that of the supernatant (S).
Protein in both supernatant and pellet fractions were precipitated with 85% methanol, and
methanol pellets subjected to SDS-PAGE and immunobloted with antibody R1.
(TIFF)
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S2 Fig. ESI-TOF analysis of recMoPrPSc-950 PK-resistant peptides. The PK digest was pre-
cipitated with methanol and the pellet dissolved in 6M Gn/HCl. The sample was then sub-
jected to HPLC and the effluent fed to an ESI-TOF detector. The inset shows the total ion
current output. The MS spectrum of the peak in at 18.9–19.6 minutes is shown. Deconvolution
of the spectrum yielded a main component with an average mass of 9400.76 Da (MH+), corre-
sponding to a peptide with the Mo PrP sequence M153-S230 (theoretical average mass: 9399.5
Da). AN Additional species with an MH+ value of +17 and likely corresponds to the same pep-
tide with one of the three Met residues present in the sequence oxidized. A minor component
with an MH+ value of 9531.61 Da might correspond to N152-S230 (theoretical average mass:
9513.6) with an oxidized methionine a component with M = 9514 Da.
(TIF)
S3 Fig. Sequences of mouse and bank vole PrP. Secondary structure of PrPC, as determined
by NMR studies (Mouse PDB 2L39; bank vole PDB 2K56): Lines placed on the PrPC sequence
indicate the location of β-sheet and α–helical regions.
(TIF)
S4 Fig. Additional epitope mapping of PK-resistant peptides from recMoPrPSc-950.
RecMoPrPSc-950 was treated with 10 μg/ml PK as described in the Materials and methods sec-
tions, and under the same conditions used for the experiments described in Fig 3. Digested
samples were subjected to Tris/Tricine SDS-PAGE, electroblotted and probed with monoclo-
nal antibody SAF84, which recognizes epitope 166–172. SAF84, as expected, recognized the
~16 and ~14.6 kDa bands corresponding to 86/98-230 and 117/119-230 fragments, and more
weakly, ~13, ~12, and ~10.2 kDa bands putatively corresponding to ~117/119-230, ~135–230,
and ~152/153-230. Essentially no bands were detected with smaller apparent MW values,
since they do not contain the (166–172) epitope. Also, none of the doubly truncated fragments
detected by 3F10, which do not include the epitope, were detected.
(TIF)
S5 Fig. Histopathological and immunohistochemical analysis of brains from bank voles
inoculated with recBVPrPSc. Two brain areas were investigated: striatium and retrosplenial
cortex. Spongiform lesion was studied by haematoxylin-eosin (H&E) staining. PrPSc aggre-
gates/deposits were observed by IHC staining (antibody 6C2). Finally astroglia activation was
determined by GFAP staining.
(TIF)
S6 Fig. MALDI spectra of tryptic digests of bands 1 to 5 of the gel shown in Fig 5, corre-
sponding to PK-treated recBVPrPSc. The bands were excised and reduced, alkylated and
digested in-gel with trypsin. Peptides were extracted, dried in vacuo, redissolved in 6M Gn/
HCl and analyzed by MALDI-TOF [35].
(TIFF)
S7 Fig. Cryo-electron microscopy of recMoPrPSc. A PK-treated MoPrPSc-17kDa sample was
concentrated by centrifugation at 19,000 g for 1 hat 4˚C (Sorvall ST 16R, Thermo Scientific).
The resulting pellet was resuspended in 10 μl PBS (Fisher Bioreagents) and stored at -20 ˚C
until microscopic examination. The sample was applied directly to a carbon-coated grid, R 2/2
Quantifoil1 (Quantifoil), and rapidly plunged into liquid ethane using a Vitrobot (Maastricht
Instruments BV). Sample analysis was performed with a JEM 2200F (JEOL) transmission
cryo-electron microscope, using an acceleration voltage of 200 KV and defocus ranging
from 21.2 to 22.5 mm, determined accurately by using enhanced power spectra. Images were
obtained with a 2k62k TM Ultrascan 1000 CCD camera (Gatan).
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Images show short, untwisted fibrils, ~10 nm wide, apparently composed of two intertwined
protofilaments, very similar to those of GPI-anchorless PrPSc [26]. Rosettes are glycogen pres-
ent as a contaminant in the liver RNA extract used as part of the conversion mixture, as
described before (Timmes et al. PLoS One. 2013 Jul 30;8(7):e71081. doi: 10.1371/journal.pone.
0071081).
(TIF)
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